rmdopen.bmj

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term ...

Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined ...
rmdopen.bmj

Cost assessment of health interventions and diseases

Health resource use and identification of related costs are two essential steps in health economics assessment. The elicited costs will be balanced with health outcome improvement and enable the ...
rmdopen.bmj

Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies

Methods Anti-Ku-positive patients were retrieved through four immunology departments. Clusters were derived from unsupervised multiple correspondence analysis, not including the disease’s diagnosis, ...
rmdopen.bmj

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3

Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...
rmdopen.bmj

MRI of shoulder girdle in polymyalgia rheumatica: inflammatory findings and their diagnostic value

Background Non-synovial inflammation as detected by MRI is characteristic in polymyalgia rheumatica (PMR) with potentially high diagnostic value. Objective The objective is to describe inflammatory ...
rmdopen.bmj

Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning

Objectives Real-world data regarding rheumatoid arthritis (RA) and its association with interstitial lung disease (ILD) is still scarce. This study aimed to estimate the prevalence of RA and ILD in ...
rmdopen.bmj

Polymyalgia rheumatica: an autoinflammatory disorder?

Polymyalgia rheumatica (PMR) is an elderly onset syndrome characterised by aching and stiffness in the shoulders and the pelvic girdle associated to increased levels of acute phase reactants and rapid ...
rmdopen.bmj

Trajectory analysis of glucocorticoid treatment highlights issues in the current tapering strategy for polymyalgia rheumatica

Objectives To identify glucocorticoid (GC) treatment patterns in patients with polymyalgia rheumatica (PMR) and explore patient profiles that may benefit from GC-sparing interventions. Methods This ...
rmdopen.bmj

Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study

Objective To evaluate the long-term efficacy of interleukin (IL)-17A inhibition with secukinumab on structural bone changes and clinical outcomes in psoriatic arthritis (PsA). Methods We conducted a ...
rmdopen.bmj

Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a ...

Objectives We aimed to evaluate whether obese patients with psoriatic arthritis (PsA) were less likely to be in remission/low disease activity (LDA). Results Among 431 patients (49.3% women), 136 ...
rmdopen.bmj

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German ...

Objective To describe the disease characteristics of patients with juvenile idiopathic arthritis (JIA) included in an inception cohort, to analyse how many patients from each JIA category reach an ...
rmdopen.bmj

Comparative evaluation of disease activity measures for adult-onset Still’s disease: a multicentre, retrospective, cohort study

Objective To comparatively evaluate recent adult-onset Still’s disease (AOSD) activity measures—Development and Validation of Disease Activity in AOSD (DAVID), Still’s Disease Activity Score (SDAS), ...